Reversal of DOACs
Reversal agents are available for dabigatran etexilate, apixaban and rivaroxaban.
- Idarucizumab is licensed for the rapid reversal of dabigatran in life-threatening or uncontrolled bleeding
- Andexanet alfa is licensed for the reversal of apixaban or rivaroxaban in life-threatening or uncontrolled bleeding
Take your subscriptions with you
Our mobile app allows you to access your interview and exam question banks wherever you are.